A trial looking at lenalidomide after a donor stem cell transplant for myeloma - LenaRIC

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Blood cancers




Phase 2

This trial is looking at lenalidomide after a stem cell transplant using cells from a donor. It is for people who have myeloma. This trial is supported by Cancer Research UK.

Doctors can treat myeloma with a stem cell transplant using cells from another person (a donor). This is called an allogeneic stem cell transplant Open a glossary item. Before having the transplant, you have a combination of chemotherapy and radiotherapy. Doctors can reduce the possible complications of a transplant by giving lower doses of chemotherapy. They call this a reduced intensity conditioning (RIC) transplant.

Lenalidomide is a type of biological therapy. It works mainly by helping the immune system target cancer cells. We know from research that lenalidomide can help people with newly diagnosed myeloma.

The researchers think that lenalidomide may also be useful for people who have a RIC allogeneic stem cell transplant to treat their myeloma.

The aims of this trial are to

  • See if having lenalidomide after a reduced intensity conditioning transplant is safe and helps to stop myeloma coming back
  • Learn more about the side effects

Who can enter

You may be able to enter this trial if you

  • Have had high dose melphalan followed by a transplant of your own bone marrow (autologous transplant) in the last 6 months and your myeloma has completely gone or nearly gone – your doctor will discuss this
  • Are able to have an allogeneic transplant with reduced intensity conditioning
  • Are well enough to be up and about for half of the day (performance status 0, 1, 2)
  • Have satisfactory blood test results
  • Are willing to use reliable contraception if there is a chance you or your partner could become pregnant
  • Are between 18 and 70 years old

You cannot enter this trial if you

  • Are able to have intensive treatment for your myeloma
  • Have had an organ transplant 
  • Are allergic to the drugs used in this trial
  • Have had an experimental drug as part of another clinical trial in the last 4 weeks
  • Have another medical condition that could affect you taking part in this trial
  • Are pregnant or breastfeeding

Trial design

This is a phase 2 trial. It will recruit 40 people in the UK. Everyone taking part will have chemotherapy and radiotherapy before having a transplant of stem cells from a donor.

You have the chemotherapy drug fludarabine. You also have drugs called ciclosporin and anti thymocyte globulin (ATG) to help damp down your immune system. You have one dose of radiotherapy to your whole body. This is called total body irradiation or TBI. Having these drugs and radiotherapy takes 4 days. On the 5th day you have the stem cell transplant.

About 1 month after your transplant you start lenalidomide. Lenalidomide is a capsule that you swallow. You take it every day for 3 weeks and then have a week without treatment. Each 4 week period is called a cycle of treatment. You can have up to 12 cycles of treatment within the first year after your transplant.

Hospital visits

You see the doctor and have some tests before starting treatment. These include

After your transplant you have a blood test once a week for 3 months, once every 2 weeks for 3 months then every month for 18 months.

At the beginning of each cycle of lenalidomide you see the doctor and have a physical examination.

You have a bone marrow test at 6, 12 and 24 months.

Side effects

The most common side effects of lenalidomide are

You can find more information about lenalidomide and side effects of a stem cell transplant on CancerHelp UK.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Mark Cook

Supported by

Cancer Research UK
Cancer Research UK Clinical Trials Unit, Birmingham
Celgene Ltd
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University Hospital Birmingham NHS Foundation Trust

Other information

This is Cancer Research UK trial number CRUK/09/026.

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 4273

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Charlie took part in a trial to try new treatments

A picture of Charlie

“I think it’s really important that people keep signing up to these type of trials to push research forward.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page